Patent ID: 7312358

Claim:
A method comprising: administering a composition comprising at least one sulfanilide of Formula I: a geometrical isomer thereof, an optically active enantiomer thereof, an optically active diastereomer thereof, a racemate of an optically active enantiomer or diastereomer thereof, or a pharmaceutically acceptable salt thereof, to a mammal in need thereof, wherein: R 1 and R 2 are aryl or heteroaryl which may be fused with 1-2 further cycloalkyl or aryl or heteroaryl groups; R 3 is selected from the group consisting of H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl aryl, C 1-C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl; R 4 and R 5 are independently selected from the group consisting of hydrogen, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl; saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected from the group consisting of N, 0, S, aryl, heteroaryl, C 1 -C 6 -alkyl aryl, and C 1 -C 6 -alkyl heteroaryl, or R 4 can be H or C 1 -C 6 alkyl, and R 5 can be —N═CR 6 R 7 , wherein: R 6 is an aryl or a heteroaryl ring carrying 1 to 5 substituents selected from the group consisting of H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, a primary amino group, a secondary amino group, a tertiary amino group, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, C 1 -C 6 -alkoxy, thioalkoxy, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2-(2-hydroxyethoxy)-ethoxy, 2-(dimethylamino)ethoxy, 2-(2-(dimethylamino)ethoxy)-ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2-sulfoxy-ethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl]ethoxy, 2-[(2-hydroxyethyl)-sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl]ethoxy, 2-[(2-carboxymethyl)sulfanyl]-ethoxy, and 2-[(2-sulfoxyethyl)sulfanyl]ethoxy; R 7 is selected from the group consisting of H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl aryl, C 1 -C 6 -alkyl heteroaryl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, acyl, aminocarbonyl, alkoxycarbonyl, aryl, heteroaryl, carboxyl, cyano, and sulfonyl; or R 6 and R 7 form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from the group consisting of N, S and 0, and which is optionally fused with an aryl, heteroaryl or 3-8 membered saturated or unsaturated cycloalkyl ring, wherein the mammal is in need of treatment for preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephritic syndrome or ocular hypertension.